Bristol-Myers Unit Settles Over Generic Cancer Drug

By Hannah Albarazi (August 20, 2021, 5:29 PM EDT) -- Bristol-Myers unit Celgene has reached a settlement with India-based Hetero Labs, marking the final settlement to come out of Celgene's 2017 lawsuit against a raft of generic-drug makers over patents for its blockbuster cancer medication Pomalyst, according to a consent judgment approved Thursday in New Jersey federal court....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!